-
公开(公告)号：KR1020080006961A
公开(公告)日：2008-01-17
申请号：KR1020060066357
申请日：2006-07-14
IPC: A61K9/70
CPC classification number: A61K9/7038 , A61K31/192 , A61K31/196
Abstract: A transdermal preparation is provided to promote the drug absorption by the skin hydration through a hydrophobic adhesive layer, show continuous and high effect of a drug by maintaining the thermodynamic activity of the hydrophobic drug in an adhesive caused by moisture discharged from skin and be able to reduce the cost and the time due to a very simple preparing process. A transdermal preparation for a hydrophobic drug comprises a supportive layer(1) which is the uppermost portion of a layered structure and has the elasticity; a hydrophobic adhesive layer(2) which is layered under the supportive layer and prevents the loss of moisture absorbed from skin and the reverse conversion of the drug; and a drug containing adhesive layer(3) which is layered under the hydrophobic adhesive layer, includes a drug and attaches the transdermal preparation to the skin and is characterized in that the drug adhesive layer includes a hydrophobic drug such as a non-steroidal antiphlogistics and an absorption promoting agent, where a hydrophobic adhesive of the hydrophobic adhesive layer is selected from the group consisting of polyisobutylene adhesive, styrene-isoprene-styrene adhesive, and styrene-butadiene-styrene adhesive, the drug containing adhesive layer is an acrylate polymer made from acrylate, hydroxypropyl acrylate, acrylamide, acrylamide vinyl acetate, vinyl derivative, methacrylate, hydroxypropyl methacrylate and methacrylamide. The preparation further comprises a release layer(4) which is layered under the drug adhesive layer and protects the drug adhesive layer before use.
Abstract translation: 提供透皮制剂以通过疏水粘合剂层通过皮肤水合促进药物吸收，通过将疏水药物的热力学活性保持在由皮肤排出的水分引起的粘合剂中，显示出药物的连续和高效果，并且能够 由于非常简单的准备过程，降低了成本和时间。 用于疏水性药物的透皮制剂包括支撑层（1），其是层状结构的最上部并具有弹性; 疏水性粘合剂层（2），其被层叠在支撑层下方并防止皮肤吸收的水分的损失和药物的逆转换; 和层叠在疏水性粘合剂层下面的药物含有粘合剂层（3）的药物包含药物，并将透皮制剂附着于皮肤，其特征在于，所述药物粘合剂层包括疏水性药物，例如非甾体消炎药， 吸水促进剂，其中疏水性粘合剂层的疏水性粘合剂选自聚异丁烯粘合剂，苯乙烯 - 异戊二烯 - 苯乙烯粘合剂和苯乙烯 - 丁二烯 - 苯乙烯粘合剂，所述药物粘合剂层是由 丙烯酸酯，丙烯酸羟丙酯，丙烯酰胺，丙烯酰胺乙酸乙烯酯，乙烯基衍生物，甲基丙烯酸酯，甲基丙烯酸羟丙酯和甲基丙烯酰胺。 该制剂还包括层叠在药物粘合剂层下面的释放层（4），并在使用前保护药物粘合剂层。
-
公开(公告)号：KR1020080006960A
公开(公告)日：2008-01-17
申请号：KR1020060066353
申请日：2006-07-14
IPC: A61K9/70
CPC classification number: A61K9/7061 , A61K47/32
Abstract: A transdermal preparation is provided to continuously allow a highly concentrated hydrophobic drug to be absorbed into skin until a patch is detached from the skin with minimized skin side effects and provide the enough adhesive capability during the time of exhibiting the medical efficacy by being attached to the skin. A transdermal preparation for a hydrophobic drug comprises a supportive layer(1) which is the uppermost portion of a layered structure and has the elasticity; a hydrophobic adhesive layer(2) which is layered under the supportive layer and prevents the loss of moisture absorbed from skin and the reverse conversion of the drug; and a drug adhesive layer(3) which is layered under the hydrophobic adhesive layer, includes a drug and attaches the transdermal preparation to the skin and is characterized in that the drug adhesive layer includes a hydrophobic drug such as a non-steroidal antiphlogistics and an acryl adhesive agent and the acryl adhesive agent includes a hydrophilic monomer promoting the skin absorption from the skin and is selected from the group consisting of acrylic acid, methyl methacrylate, ethyl acrylate, hydroxyethyl acrylate, butyl acrylate, octyl acrylate, 2-ethylhexyl acrylate, and hexyl acrylate. The preparation further comprises a release layer(4) which is layered under the drug adhesive layer and protects the drug adhesive layer before use.
Abstract translation: 提供透皮制剂以连续地允许高度浓缩的疏水性药物被吸收到皮肤中，直到贴片从皮肤上分离出来，使皮肤的副作用最小化，并且在展示医疗功效的时间期间提供足够的粘合能力， 皮肤。 用于疏水性药物的透皮制剂包括支撑层（1），其是层状结构的最上部并具有弹性; 疏水性粘合剂层（2），其被层叠在支撑层下方并防止皮肤吸收的水分的损失和药物的逆转换; 以及层叠在疏水性粘合剂层下方的药物粘合剂层（3），包括药物，并且将透皮制剂附着于皮肤，其特征在于，所述药物粘合剂层包括疏水性药物，例如非甾体消炎药和 丙烯酸粘合剂和丙烯酸粘合剂包括促进皮肤吸收皮肤的亲水单体，并且选自丙烯酸，甲基丙烯酸甲酯，丙烯酸乙酯，丙烯酸羟乙酯，丙烯酸丁酯，丙烯酸辛酯，丙烯酸2-乙基己酯， 和丙烯酸己酯。 该制剂还包括层叠在药物粘合剂层下面的释放层（4），并在使用前保护药物粘合剂层。
-
公开(公告)号：KR1020080004078A
公开(公告)日：2008-01-09
申请号：KR1020060062567
申请日：2006-07-04
Applicant: (주)아모레퍼시픽
CPC classification number: A61K9/1682 , A61K9/0002 , A61K47/6925 , A61K47/6951
Abstract: A sustained-release porous microparticle for pulmonary delivery of a charged protein drug is provided to rapidly deliver the charged protein drug to epidermal cells in deep part of the lung without macrophage damage, thereby maintaining stability of the protein drug and continuously releasing the protein drug for a long period of time. A sustained-release porous microparticle for pulmonary delivery of a charged protein drug is prepared by (1) solubilizing cyclodextrin derivatives, ionic polysaccharides and a charged protein drug in water to prepare an inner water phase, (2) adding biodegradable polymer into organic solvent to prepare an organic phase, (3) mixing the inner water phase of step (1) with the organic phase of step (2) to prepare a first emulsion, and (4) spraying the first emulsion to an outer aqueous continuous phase containing an aqueous coating material, and has an average particle diameter of 5-100 mum.
Abstract translation: 提供用于肺部递送带电荷的蛋白质药物的持续释放多孔微粒以迅速将带电荷的蛋白质药物递送至深部肺部的表皮细胞而无巨噬细胞损伤，从而保持蛋白质药物的稳定性并连续释放蛋白质药物 很长一段时间。 通过（1）将环糊精衍生物，离子多糖和带电荷的蛋白质药物溶于水中制备内水相制备用于肺部递送带电荷蛋白药物的持续释放多孔微粒，（2）将可生物降解的聚合物加入到有机溶剂中 制备有机相，（3）将步骤（1）的内部水相与步骤（2）的有机相混合以制备第一乳液，和（4）将第一乳液喷雾到含有水相的外部含水连续相中 涂料，平均粒径为5〜100μm。
-
公开(公告)号：KR1020070051402A
公开(公告)日：2007-05-18
申请号：KR1020050108884
申请日：2005-11-15
Applicant: (주)아모레퍼시픽
CPC classification number: A61K9/1647 , A61K9/19 , A61K47/14
Abstract: 본 발명은 수크로스 아세테이트 이소부티레이트(sucrose acetate isobutyrate, SAIB)를 포함하는 미세입자의 제조방법에 관한 것으로, (1) 단백질 약물을 수성 용액에 녹여 수상(water phase)을 제조하는 단계; (2) 수크로스 아세테이트 이소부티레이트와 생분해성 고분자를 유기용매에 녹여 유상(oil phase)을 제조하는 단계; (3) 단계 (1)의 수상을 단계 (2)의 유상에 첨가하여 1차 에멀젼을 형성하는 단계; 및 (4) 1차 에멀젼을 외부 수성 연속상에 첨가하여 2차 에멀젼을 형성한 후, 2차 에멀젼 중에 생성된 고형물을 분리하는 단계를 포함하는 본 발명에 의하면, 약물의 초기 과다 방출 없이 생리적 활성을 유지하면서 약물을 장기간 지속적으로 방출할 수 있는 서방형 미세입자를 제조할 수 있다.
수크로스 아세테이트 이소부티레이트, 생분해성 고분자, 서방형 미세입자, 지속적 약물 방출-
15.发明公开비스포스포네이트-함유 고분자 미립구를 포함하는 골-관련질환 치료 또는 예방용 서방 효과를 갖는 주사제 失效用于治疗或预防包含含有相对含磷酸盐的聚合物微生物的骨相关疾病的可持续发布注意事项
公开(公告)号：KR1020060045910A
公开(公告)日：2006-05-17
申请号：KR1020050037718
申请日：2005-05-04
Applicant: (주)아모레퍼시픽
CPC classification number: A61K9/0019 , A61K9/1641 , A61K47/26
Abstract: 본 발명은 수용성 고분자 및 친수성 계면활성제를 포함하는 수용액에 비스포스포네이트를 용해 및 분산시켜 제조한 고분자 용액을, 생분해성 고분자 및 소수성 계면활성제를 포함하는 1차 유기용매 내에 2차 유기용매를 가하여 제조된 고분자 용액에 가하여 1차 에멀젼 용액 (water-in oil (W/O))을 제조하고, 1차 에멀젼 용액을 외부 연속상에 분산시켜 제조한 비스포스포네이트-함유 고분자 미립구를 포함하는, 골-관련 질환 치료 또는 예방용 서방 효과를 갖는 주사제에 관한 것이다.
상기 주사제는 1회 투여로 생체내에서 4주 이상의 지속적 서방출 효과를 나타내므로, 매일 투여되는 경구제에 비해 상당히 적은 투여 횟수 및 적은 투여 용량으로, 또한 비스포스포네이트의 직접 주사에 비해 국소 독성이 상당히 감소되어 비스포스포네이트 약물이 나타내는 치료 또는 예방 활성을 얻을 수 있다.
비스포스포네이트, 미립구, 서방, 주사제-
Patent Agency Ranking
公开(公告)号：KR101616995B1
公开(公告)日：2016-06-07
申请号：KR1020107017336
申请日：2008-12-03
Applicant: (주)아모레퍼시픽
CPC classification number: A61K38/20 , A23L2/52 , A23L33/105 , A23L33/15 , A23L33/16 , A23L33/40 , A23V2002/00 , A61K8/64 , A61K9/0019 , A61K9/0095 , A61K9/1623 , A61K9/2018 , A61K9/2059 , A61K9/4866 , A61Q19/06 , A23V2200/332
Abstract: 본발명은인터루킨 17(interleukin-17, IL-17)을유효성분으로함유하는슬리밍용조성물에관한것이다. 본발명에따른슬리밍용조성물의유효성분인유의적인지방세포의분화억제, 및분화된지방세포내의지질체수준감소를통해, 우수한슬리밍효과를발휘할수 있다.
-
公开(公告)号：KR101439472B1
公开(公告)日：2014-09-15
申请号：KR1020070123865
申请日：2007-11-30
Applicant: (주)아모레퍼시픽
Abstract: 본 발명은 서열번호: 1의 염기서열 중에서 선택된 활성 부위를 포함하는 프로모터; 상기 프로모터 및 리포터 유전자를 포함하는 벡터; 상기 벡터를 포함하는, 지방분해를 촉진하는 후보물질을 검색하기 위한 키트; 및 상기 벡터를 이용하여 지방분해를 촉진하는 후보물질을 검색하는 방법에 관한 것이다.
본 발명에서 제공되는 프로모터는 퍼록시좀 증식인자-활성화 수용체-감마(peroxisome proliferator-activated receptor-gamma, PPAR-γ)와 결합하여 멜라노코르틴 2 수용체 부속 단백질(melanocortin 2 receptor accessory protein, Mrap) 유전자의 발현을 증진시켜 부신피질자극 호르몬(Adrenocorticotropic hormone, ACTH)에 의한 지방 분해를 촉진하기 때문에, 상기 프로모터를 적절한 리포터 유전자와 융합시킨 벡터를 이용하면 지방 분해를 촉진하는 후보물질을 효과적으로 검색할 수 있으며, 이를 통해 얻어진 후보물질은 Mrap 유전자의 발현을 증진시켜 ACTH에 의한 지방 분해를 촉진하여, 비만 관련 질환을 치료 및 예방할 수 있다.-
18.发明授权
公开(公告)号：KR101349198B1
公开(公告)日：2014-01-09
申请号：KR1020087030865
申请日：2006-12-08
Applicant: (주)아모레퍼시픽
IPC: A61K31/661 , C07K14/47 , C12Q1/68 , A61P17/00
CPC classification number: C12Q1/18 , G01N33/92 , G01N2405/08 , G01N2800/202
Abstract: SPC는 아토피성 피부염 환자에게서 인간 베타 디펜신(HBD-1, HBD-2, HBD-3 및 HBD-4), 카텔리시딘(LL-37) 및 덤시딘의 발현을 억제시키므로, SPC 길항제는 AMPs의 발현 감소 관련 질환의 예방 및 치료에 유용하다.
-
公开(公告)号：KR1020090056584A
公开(公告)日：2009-06-03
申请号：KR1020070123798
申请日：2007-11-30
Applicant: (주)아모레퍼시픽 , 재단법인서울대학교산학협력재단
CPC classification number: A61K31/16
Abstract: A pharmaceutical composition regulating the activity of sphingosylphosphorylcholine(SPC) is provided to regulate cell proliferation, inflammation and pruritus and treat inflammmatin or pruritus of dermatitis such as atopic dermatitis. A pharmaceutical composition which regulates the activity of sphingosylphosphorylcholine(SPC) comprises a compound of the chemical formula 1 or its pharmaceutically allowable salt. In the chemical formula 1, X is O or S, Y is CH2 or carbonyl. R1 is hydrogen or C1-10 alkyl, R2 is hydrogen or methyl, but when X is O, either R1 or R2 cannot be hydrogen, R3 is C1-4 alkyl. A method for manufacturing a compound of the chemical formula 1a comprises: a step of reacting a compound of the chemical formula 2 and a compound of the chemical formula 3 under the presence of base to obtain a compound of the chemical formula 4; a step of stirring the compound of the chemical formula 4 under the presence of base to obtain a compound of the chemical formula 5; and a step of performing the peptide bond between the compound of the chemical formula 5 and a compound of the chemical formula 6 to obtain the compound of the chemical formula 1a.
Abstract translation: 提供调节肌动蛋白磷酰胆碱（SPC）活性的药物组合物，用于调节细胞增殖，炎症和瘙痒，并治疗诸如特应性皮炎等炎性炎症或皮炎瘙痒症。 调节鞘糖基磷酰胆碱（SPC）活性的药物组合物包含化学式1的化合物或其药学上可允许的盐。 在化学式1中，X为O或S，Y为CH 2或羰基。 R1是氢或C1-10烷基，R2是氢或甲基，但当X是O时，R1或R2不能是氢，R3是C1-4烷基。 制备化学式1a化合物的方法包括：使化学式2的化合物与化学式3化合物在碱存在下反应得到化学式4的化合物的步骤; 在碱的存在下搅拌化学式4的化合物以获得化学式5的化合物的步骤; 在化学式5的化合物与化学式6的化合物之间进行肽键的步骤，得到化学式1a的化合物。
-
20.发明公开
公开(公告)号：KR1020080097420A
公开(公告)日：2008-11-05
申请号：KR1020087019182
申请日：2007-02-14
Applicant: (주)아모레퍼시픽
IPC: A61K31/17 , A61K31/765 , A61P17/00
CPC classification number: A61K9/0014 , A61K31/17 , A61K47/10 , A61K47/12 , A61K47/20 , A61K47/26 , A61K47/32
Abstract: A composition for external application for treating and preventing the pruritus or irritant skin disease is provided to have excellent fluxes and stability by containing the thiourea derivative and to be useful in pruritus or irritant skin disease. A composition for external application of O/w-shaped emulsion form comprises (1) drug expressed as a compound of a chemical formula 1, (2) a component selected from a group consisting of squalene, dimethicone, propylene glycol, butylene glycol and mineral oil, (3) a component selected from a group consisting of polyethylene glycol 400, polyoxyethylene alkyl ether, cetyl alcohol and solbitan stearate, (4) water and (5) a component selected from a group consisting of ethanol, twin 60, carbomer 940, EDTA.2Na and triethanolammine.
Abstract translation: 提供用于治疗和预防瘙痒或刺激性皮肤病的外用组合物，通过含有硫脲衍生物具有优异的通量和稳定性，并且可用于瘙痒或刺激性皮肤病。 用于外用O / W型乳液形式的组合物包括（1）以化学式1化合物表示的药物，（2）选自角鲨烯，聚二甲基硅氧烷，丙二醇，丁二醇和矿物质的组分 油，（3）选自聚乙二醇400，聚氧乙烯烷基醚，鲸蜡醇和硬脂酸solbitan的组分，（4）水和（5）选自乙醇，双螺杆菌60，卡波姆940 ，EDTA.2Na和三乙醇胺。
-
-
-
-
-
-
-
-
-
Search Results
81
records
(took 0.028 seconds)
